Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/220171
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJanin, Maxime-
dc.contributor.authorEsteller, Manel-
dc.contributor.authorDavalos, Veronica-
dc.date.accessioned2025-04-01T15:58:23Z-
dc.date.available2025-04-01T15:58:23Z-
dc.date.issued2023-06-28-
dc.identifier.issn0167-7659-
dc.identifier.urihttps://hdl.handle.net/2445/220171-
dc.description.abstractMost of the cancer-associated mortality and morbidity can be attributed to metastasis. The role of epigenetic and epitranscriptomic alterations in cancer origin and progression has been extensively demonstrated during the last years. Both regulations share similar mechanisms driven by DNA or RNA modifiers, namely writers, readers, and erasers; enzymes responsible of respectively introducing, recognizing, or removing the epigenetic or epitranscriptomic modifications. Epigenetic regulation is achieved by DNA methylation, histone modifications, non-coding RNAs, chromatin accessibility, and enhancer reprogramming. In parallel, regulation at RNA level, named epitranscriptomic, is driven by a wide diversity of chemical modifications in mostly all RNA molecules. These two-layer regulatory mechanisms are finely controlled in normal tissue, and dysregulations are associated with every hallmark of human cancer. In this review, we provide an overview of the current state of knowledge regarding epigenetic and epitranscriptomic alterations governing tumor metastasis, and compare pathways regulated at DNA or RNA levels to shed light on a possible epi-crosstalk in cancer metastasis. A deeper understanding on these mechanisms could have important clinical implications for the prevention of advanced malignancies and the management of the disseminated diseases. Additionally, as these epi-alterations can potentially be reversed by small molecules or inhibitors against epi-modifiers, novel therapeutic alternatives could be envisioned.-
dc.format.extent42 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherSpringer Science + Business Media-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1007/s10555-023-10120-3-
dc.relation.ispartofCancer and Metastasis Reviews, 2023, vol. 42, p. 1071-1112-
dc.relation.urihttps://doi.org/10.1007/s10555-023-10120-3-
dc.rightscc by (c) Janin, Maxime et al., 2023-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.sourceArticles publicats en revistes (Ciències Fisiològiques)-
dc.subject.classificationTumors-
dc.subject.classificationMetàstasi-
dc.subject.classificationMetilació-
dc.subject.classificationEpigenètica-
dc.subject.otherTumors-
dc.subject.otherMetastasis-
dc.subject.otherMethylation-
dc.subject.otherEpigenetics-
dc.titleCancer metastasis under the magnifying glass of epigenetics and epitranscriptomics-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec746178-
dc.date.updated2025-04-01T15:58:23Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid37369946-
Appears in Collections:Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
853481.pdf1.83 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons